Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical (300937.SZ) announced a pre-reduction, with an expected annual net profit of 14.5 to 19.5 million yuan, a year-on-year decrease of 67.24% to 75.64%.

20/01/2025

GMT Eight

Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical (300937.SZ) disclosed its performance forecast for 2024, with the company expecting a net profit attributable to shareholders of the listed company of 14.5 million to 19.5 million yuan, a year-on-year decrease of 67.24% to 75.64%; after deducting non-recurring gains and losses, the net profit is expected to be 8.75 million to 12.75 million yuan, a year-on-year decrease of 76.40% to 83.81%.

JIUYUAN GENE (02566): Jixinfen approved for market by the National Medical Products Administration.

HNAC Technology (300490.SZ) issues a profit warning, expecting a net loss of 360 million to 420 million yuan for the fiscal year 2024, with the loss widening.

Contact: contact@gmteight.com

Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical (300937.SZ) announced a pre-reduction, with an expected annual net profit of 14.5 to 19.5 million yuan, a year-on-year decrease of 67.24% to 75.64%.

RECOMMEND

HK Stock Market Move | HK ASIA HLDGS(01723) resumed trading with a high opening, up more than 64%, receiving a discount of about 5.26% to fully purchase the offer.

HK Stock Market Move | COUNTRY GARDEN (02007) resumes trading with a more than 3% increase, the company says it has implemented multiple plans and measures to alleviate liquidity pressure.

HK Stock Market Move | LINGBAO GOLD (03330) opened nearly 14% higher after a profit surge, with an expected year-on-year net profit growth of around 110% to 140%.